Substance Use Disorders (SUD)

Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives

This quantitative interview study (n=1141) applied a machine learning tool to analyze written reports of psychedelic experiences and predicted whether the participants could reduce substance abuse in response to using psychedelics with a 65% accuracy across three independently trained Natural Language Processing models.

Authors

  • Albert Garcia-Romeu
  • Matthew Johnson

Published

The American Journal of Drug and Alcohol Abuse
individual Study

Abstract

Background

Experiences with psychedelic drugs, such as psilocybin or lysergic acid diethylamide (LSD), are sometimes followed by changes in patterns of tobacco, opioid, and alcohol consumption. But, the specific characteristics of psychedelic experiences that lead to changes in drug consumption are unknown.

Objective

Determine whether quantitative descriptions of psychedelic experiences derived using Natural Language Processing (NLP) would allow us to predict who would quit or reduce using drugs following a psychedelic experience.

Methods

We recruited 1141 individuals (247 female, 894 male) from online social media platforms who reported quitting or reducing using alcohol, cannabis, opioids, or stimulants following a psychedelic experience to provide a verbal narrative of the psychedelic experience they attributed as leading to their reduction in drug use. We used NLP to derive topic models that quantitatively described each participant’s psychedelic experience narrative. We then used the vector descriptions of each participant’s psychedelic experience narrative as input into three different supervised machine learning algorithms to predict long-term drug reduction outcomes.

Results

We found that the topic models derived through NLP led to quantitative descriptions of participant narratives that differed across participants when grouped by the drug class quit as well as the long-term quit/reduction outcomes. Additionally, all three machine learning algorithms led to similar prediction accuracy (~65%, CI = ±0.21%) for long-term quit/reduction outcomes.

Conclusions

Using machine learning to analyze written reports of psychedelic experiences may allow for accurate prediction of quit outcomes and what drug is quit or reduced within psychedelic therapy.

Available with Blossom Pro

Research Summary of 'Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives'

Introduction

Research indicates that psychedelics can produce meaningful reductions in problematic substance use, with open-label and observational studies reporting improvements in tobacco, alcohol, and other substance use following experiences with agents such as psilocybin and LSD. Prior work has linked therapeutic benefits to acute subjective qualities of the psychedelic experience—particularly so-called mystical-type effects characterised by unity, positive mood, and ineffability—but objectively measuring those subjective experiences during sessions is difficult. Automated speech analysis during acute drug effects and post-session narrative analysis have both been proposed as ways to quantify subjective experience, and natural language processing (NLP) offers a potentially efficient, generalisable method to do so. Cox and colleagues set out to determine whether quantitative descriptions of retrospective psychedelic session narratives derived via NLP could (1) distinguish which drug class a person subsequently reduced or quit, (2) distinguish the extent of reduction/quit outcomes, and (3) predict long-term quit/reduction outcomes when those NLP outputs are used as inputs to supervised machine learning (ML) algorithms. The analysis used a large convenience sample of retrospective written narratives from people who reported a psychedelic experience as preceding a reduction or cessation in substance use.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (17)

Papers cited by this study that are also in Blossom

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Assessment of addiction severity among ritual users of ayahuasca

Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)

222 cited
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

A review of the clinical effects of psychotomimetic agents

Osmond, H. · Annals of the New York Academy of Sciences (2010)

296 cited
A window into the intoxicated mind? Speech as an index of psychoactive drug effects

Bedi, G., Cecchi, G. A., Slezak, D. F. et al. · Neuropsychopharmacology (2014)

89 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

52 cited
Show all 17 references
Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)

211 cited
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use

Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)

117 cited
LSD-assisted psychotherapy in patients with terminal cancer

Grof, S., Goodman, L. E., Richards, W. A. · Pharmacopsychiatry (1973)

The association of psychedelic use and opioid use disorders among illicit users in the United States

Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)

Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)

562 cited
Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution

Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)

Cited By (5)

Papers in Blossom that reference this study

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V. et al. · Addiction Biology (2022)

Natural language signatures of psilocybin microdosing

Sanz, C., Cavanna, F., Muller, S. et al. · Psychopharmacology (2022)

11 cited
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.